Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Rating of “Moderate Buy” from Analysts

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $18.75.

KLRS has been the subject of several research reports. Wall Street Zen lowered Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 13th. TD Cowen initiated coverage on shares of Kalaris Therapeutics in a report on Monday, June 15th. They issued a “buy” rating for the company. Finally, Weiss Ratings raised shares of Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 24th.

Kalaris Therapeutics Stock Performance

Shares of Kalaris Therapeutics stock opened at $2.90 on Friday. Kalaris Therapeutics has a 1 year low of $2.81 and a 1 year high of $11.88. The firm’s 50-day simple moving average is $3.71 and its 200-day simple moving average is $4.77. The firm has a market cap of $69.05 million, a PE ratio of -1.44 and a beta of 0.22.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. On average, equities analysts predict that Kalaris Therapeutics will post -1.99 earnings per share for the current year.

Institutional Investors Weigh In On Kalaris Therapeutics

Several large investors have recently added to or reduced their stakes in KLRS. Velan Capital Investment Management LP boosted its holdings in shares of Kalaris Therapeutics by 38.9% during the second quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock valued at $102,000 after acquiring an additional 7,000 shares during the period. Sigma Planning Corp acquired a new stake in shares of Kalaris Therapeutics in the 2nd quarter worth about $41,000. WealthTrust Asset Management LLC bought a new stake in Kalaris Therapeutics in the 1st quarter valued at about $72,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Kalaris Therapeutics during the 2nd quarter valued at about $122,000. Finally, Stonepine Capital Management LLC bought a new position in Kalaris Therapeutics in the 2nd quarter worth about $122,597. 66.05% of the stock is owned by institutional investors and hedge funds.

Kalaris Therapeutics Company Profile

Kalaris Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases and other serious eye disorders. Its research programs are aimed at addressing diseases in which abnormal blood-vessel growth or leakage can impair vision.

The company’s activities include the discovery and clinical development of investigational ophthalmic medicines intended to improve outcomes for patients with retinal conditions. Kalaris Therapeutics has not yet established a broad portfolio of marketed products, and its principal programs remain in development.

Publicly available information about the company’s broader operating history, geographic reach and leadership is limited.